Otros idiomas Eupraxia Pharmaceuticals Inc.

Acciones

EPRX

CA29842P1053

Mercado cerrado - Toronto S.E. Otros sitios de cotización 21:59:50 17/05/2024			Varia. Cinco días.	Varia. 1 de enero.
4 ^CAD	+1,01 %		+1,27 %	-25,51 %

08/05	Eupraxia Pharmaceuticals Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
08/04	Top Premarket Decliners	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024	14/05
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update	08/05
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Eupraxia Pharmaceuticals Forms Gastrointestinal Clinical Advisory Board	02/05
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board	02/05
Eupraxia Pharmaceuticals : Name and Address of Company - Form 6-K	08/04
Top Premarket Decliners	08/04
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference	08/04
Eupraxia Pharmaceuticals Inc.(NasdaqCM:EPRX) added to NASDAQ Composite Index	08/04
Eupraxia Pharmaceuticals Inc. Brief: Begins Trading on Nasdaq Today	05/04
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today	05/04
Eupraxia Pharmaceuticals Inc. Brief: Says to Begin Trading on Nasdaq on April 5, 2024	03/04
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024	03/04
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024	03/04
Eupraxia Pharmaceuticals Inc. Brief: Says incurred a net loss of US$10.6 million for Q4, versus $7.8 million for the three months ended December 31, 2022	01/04
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results	01/04
Eupraxia Pharmaceuticals : Name and Address of Company - Form 6-K	18/03
Eupraxia Pharmaceuticals Completes Overnight Marketed Offering	15/03
Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million	15/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Eupraxia Pharmaceuticals Inc.

Acciones

EPRX

CA29842P1053

Otros idiomas

Filtros